Important Notice for ESSA Pharma Inc. (EPIX) Shareholders: Potential Class Action Lawsuit
New York, NY – The Gross Law Firm, a leading national securities fraud law firm, issues this notice to inform shareholders of ESSA Pharma Inc. (EPIX) who purchased shares during the period from September 15, 2023 to November 30, 2024, inclusive (the “Class Period”).
If you are a shareholder who purchased EPIX shares during the Class Period, you may be entitled to serve as a lead plaintiff in a class action lawsuit against ESSA Pharma Inc. over alleged securities law violations. The Gross Law Firm invites you to contact the firm to discuss your rights and potential remedies.
Background
ESSA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer and other diseases. During the Class Period, EPIX made several public statements regarding its clinical trial progress and financial projections.
Alleged Securities Law Violations
The Gross Law Firm alleges that these statements were materially false and misleading because they failed to disclose adverse information about EPIX’s clinical trials, financial condition, and business prospects. Specifically, it is alleged that:
- EPIX failed to disclose that its lead drug candidate, EPI-5895, was experiencing significant safety concerns and efficacy issues in clinical trials;
- EPIX misrepresented the progress of its clinical trials and the likelihood of regulatory approval;
- EPIX failed to disclose material financial information, including its cash burn rate and the need for additional financing;
As a result of these alleged false and misleading statements, EPIX stock traded at artificially inflated prices during the Class Period. When the truth was revealed, the price of EPIX shares dropped significantly.
Possible Impact on Shareholders
If you purchased EPIX shares during the Class Period, you may have suffered significant losses. You may be able to recover your losses as a lead plaintiff in a class action lawsuit against ESSA Pharma Inc. The Gross Law Firm encourages you to contact the firm to discuss your potential claim.
Potential Impact on the World
The alleged securities law violations by ESSA Pharma Inc. could have far-reaching implications for the biopharmaceutical industry as a whole. If the allegations are proven, it could lead to increased scrutiny of clinical trial data and disclosures, as well as potential regulatory action against EPIX and other companies.
Conclusion
Shareholders of ESSA Pharma Inc. who purchased shares during the Class Period are encouraged to contact The Gross Law Firm to discuss their potential claim. The firm represents shareholders nationwide who have suffered significant losses due to securities fraud, and it is committed to fighting for justice on their behalf. With extensive experience in securities litigation, The Gross Law Firm is uniquely positioned to help EPIX shareholders recover their losses.
If you wish to learn more about this class action, please contact The Gross Law Firm by emailing the lead attorney, Brian Gross, at [email protected], or by calling toll-free at 855-391-0530. You may also visit the firm’s website at
This notice is not a solicitation for an offer to buy or sell securities, and it is not legal advice. Shareholders are encouraged to consult with their own legal counsel regarding their rights and potential remedies.
The Gross Law Firm represents investors worldwide, and the firm’s attorneys are admitted to practice in New York, New Jersey, and Pennsylvania. The firm has offices in New York, New Jersey, and Pennsylvania.
About The Gross Law Firm: The Gross Law Firm is a leading national securities fraud law firm that represents institutional and individual investors who have suffered significant losses due to securities fraud, breaches of fiduciary duty, and other financial misconduct. The firm has recovered billions of dollars for its clients and is committed to fighting for justice in the securities industry.
